METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME

摘要

The invention provides administration to a subject of a pharmaceutical formulation comprising diazoxide to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological and metabolic outcomes in the treatment of diseases or conditions involving K_ATP channels. Also provided are methods of treating subjects having Prader-Willi Syndrome or Smith-Magenis syndrome by administering to said subject a pharmaceutical formulation comprising diazoxide, that achieve these outcomes while reducing the incidence of adverse effects in treated individuals.